0001193125-24-005614.txt : 20240110 0001193125-24-005614.hdr.sgml : 20240110 20240110070029 ACCESSION NUMBER: 0001193125-24-005614 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240109 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240110 DATE AS OF CHANGE: 20240110 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Seres Therapeutics, Inc. CENTRAL INDEX KEY: 0001609809 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 274326290 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37465 FILM NUMBER: 24524846 BUSINESS ADDRESS: STREET 1: 200 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617 945 9626 MAIL ADDRESS: STREET 1: 200 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: Seres Health, Inc. DATE OF NAME CHANGE: 20140603 8-K 1 d129973d8k.htm 8-K 8-K
false 0001609809 0001609809 2024-01-09 2024-01-09

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 9, 2024

 

 

SERES THERAPEUTICS, INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

 

Delaware   001-37465   27-4326290

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

101 Cambridgepark Drive

Cambridge, MA

   02140
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: (617) 945-9626

 

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange

on which registered

Common stock, par value $0.001 per share   MCRB   The Nasdaq Stock Market LLC (Nasdaq Global Select Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

Item 2.02.

Results of Operations and Financial Condition.

On January 9, 2024, Seres Therapeutics, Inc. (the “Company”) issued a press release in which the Company announced, among other things, that based on preliminary financial results, the Company had net sales of VOWST of approximately $10.4 million (unaudited) in the fourth quarter of 2023, and preliminary cash, cash equivalents and investments of approximately $128 million (unaudited) as of December 31, 2023. The full text of the press release was posted in the “Investors and News” portion of its website at www.serestherapeutics.com. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

These preliminary financial results are based on preliminary unaudited information and the Company’s current estimate of its results for the year ended December 31, 2023, and remain subject to change based on the completion of closing and review procedures and the execution of the Company’s internal control over financial reporting. The Company’s independent registered public accounting firm has not conducted an audit or review of, and does not express an opinion or any other form of assurance with respect to, these preliminary estimates.

On January 9, 2024, the Company also posted an updated corporate presentation including the foregoing preliminary financial results in the “Investors and News” portion of its website at www.serestherapeutics.com, and intends to present the preliminary financial results at the 42nd annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024, at 12:45 p.m. Eastern Time / 9:45 a.m. Pacific Time. The live presentation and archived webcast will be accessible from the Company’s website at www.serestherapeutics.com. A copy of the presentation is attached as Exhibit 99.2 to this Current Report on Form 8-K and incorporated herein by reference.

The information in Item 2.02 of this Current Report on Form 8-K, including Exhibits 99.1 and 99.2 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Current Report on Form 8-K that do not relate to matters of historical fact should be considered forward-looking statements, including statements about the Company’s anticipated financial results for the year ended December 31, 2023, the Company’s attendance at any conferences, and the content of the information that the Company may present at conferences. These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the impact of unfavorable economic conditions; the completion of closing and review procedures and the execution of the Company’s internal control of financial reporting; and other factors discussed under the caption “Risk Factors” in our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”), on November 2, 2023, and our other reports filed with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this Current Report on Form 8-K. Any such forward-looking statements represent management’s estimates as of the date of this Current Report on Form 8-K. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this Current Report on Form 8-K.

 

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits.

The following Exhibits 99.1 and 99.2 relate to Item 2.02 and shall be deemed to be furnished, and not filed:

 

Exhibit

No.

    Description
99.1    Press Release, dated January 9, 2024
99.2    Seres Therapeutics, Inc. Corporate Presentation as of January 2024 (incorporated by reference to Exhibit 99.1 to the Company’s Current Report on Form 8-K filed on January 9, 2024)
104    Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: January 10, 2024   SERES THERAPEUTICS, INC.
    By:  

/s/ Thomas J. DesRosier

    Name:   Thomas J. DesRosier
    Title:   Chief Legal Officer and Executive Vice President
 EX-99.1 2 d129973dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

Seres Therapeutics Announces VOWST™ Commercial Launch Update and US FDA Fast Track Designation for SER-155

VOWST preliminary net sales of approximately $10.4 million (unaudited) for the fourth quarter of 2023

Significant adoption of VOWST since commercial launch in June 2023 through year-end 2023 with 2,833 patient enrollment forms received and 2,015 new patient starts

SER-155 Phase 1b placebo-controlled Cohort 2 data readout anticipated in third quarter of 2024

Seres to Present at 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024

CAMBRIDGE, Mass., Jan. 9, 2024 — Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced preliminary key VOWST (fecal microbiota spores, live-brpk) launch metrics and receipt of US FDA Fast Track Designation for SER-155 ahead of its presentation at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10th. VOWST, the first FDA approved orally administered microbiome therapeutic, received FDA approval in April of 2023 and is indicated to prevent the recurrence of Clostridioides difficile infection (CDI) in adults following antibacterial treatment for recurrent CDI (rCDI). VOWST is being commercialized by Nestlé Health Science in collaboration with Seres. SER-155 builds upon the clinical success of VOWST and is an investigational oral, cultivated microbiome therapeutic designed to prevent GI-associated bacterial infections, including blood stream infections, and to reduce the incidence of severe acute graft-versus-host disease (GvHD) in immunocompromised patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT).

“In 2023, VOWST received FDA approval with a broad indication, which includes use in first recurrence patients. We are thrilled, along with our collaborators at Nestlé Health Science, to help patients exit the vicious cycle of recurrence that happens far too often with CDI,” said Eric Shaff, President and Chief Executive Officer at Seres. “The strong adoption of VOWST since launch is indicative of the high unmet need in this category, the highly compelling clinical profile of VOWST, and the early success we have demonstrated in educating healthcare providers, payers and patients about this new treatment option.”

“Seres is looking forward to 2024 as we continue to build on our initial VOWST commercial success. The SER-155 Cohort-2 readout is expected in the third quarter, and we are excited to announce receipt of Fast Track Designation for SER-155 to reduce the risk of infection and GvHD in allo-HSCT patients. Fast Track Designation is awarded to expedite both drug development and FDA review of drugs to treat serious conditions and fulfill an unmet medical need.”

“I’m pleased with the significant progress made on our launch priorities since the commercial availability of VOWST in June,” said Terri Young, Ph.D., Chief Commercial and Strategy Officer at Seres. “Healthcare provider education efforts have scaled creating a positive customer experience with faster and higher conversion of enrollments to new patient starts. We look forward to continuing our efforts in 2024 with Nestlé Health Science and expect to make significant progress increasing the adoption of VOWST and achieving additional payer coverage.”

Seres will present at the 42nd annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024, at 12:45 pm ET / 9:45 am PT. The live presentation and archived webcast will be accessible from the company’s website at www.serestherapeutics.com.

VOWST Commercial Performance

Broad demand for VOWST has been observed across rCDI patients and healthcare providers since product launch in June 2023:

 

  •  

Fourth quarter net sales were approximately $10.4 million (unaudited) and reflected a gross-to-net reduction of 11%. Total 2023 net sales since launch in June were approximately $19.6 million (unaudited) and reflected a gross-to-net reduction of 13%.

 

  •  

Fourth quarter completed prescription enrollment forms received for VOWST were 1,322; of those 1,082 resulted in new patient starts by year-end 2023.

 

  •  

Total 2023 completed prescription enrollment forms received for VOWST since launch were 2,833; of those 2,015 resulted in new patient starts by year-end 2023.

 

  •  

In 2023, prescription enrollment forms were submitted by approximately 1,330 unique healthcare providers (HCPs) since launch; approximately 340 HCPs have prescribed VOWST to more than one patient.

Seres 2023 Highlights

 

  •  

VOWST received FDA approval in April as the first and only FDA approved orally administered microbiome therapeutic to prevent recurrence of CDI in patients with rCDI, after treatment with standard of care antibacterials.

 

  •  

Strong adoption of VOWST since commercial launch in June 2023 with broad utilization, continued quarter over quarter growth, and significant progress achieving patient access.

 

  •  

Production of VOWST commercial supply enabled a strong commercial launch within weeks of approval; progress in expansion of VOWST manufacturing capacity.

  •  

SER-155 Phase 1b Cohort 1 clinical data showed favorable tolerability, successful drug bacteria engraftment, and a substantial reduction in pathogen domination in the gastrointestinal microbiome supporting progression to the placebo-controlled Cohort 2.

 

  •  

SER-155 received US FDA Fast Track Designation.

 

  •  

Completed strategic restructuring of Company to focus resources and investment on continued VOWST growth, completion of SER-155 Phase 1b study and supporting longer-term business sustainability.

 

  •  

Named to “TIME 100 Most Influential Companies” list of 100 companies making an extraordinary impact around the world.

Anticipated 2024 Milestones

 

  •  

Expect continued progress in 2024 towards commercial priorities including:

 

  •  

Expansion of the number of HCPs prescribing VOWST as a result of new efforts scaled in Q4 2023 such as strengthened promotional campaigns and expanded reach of HCP and patient digital promotion.

 

  •  

Growth of VOWST utilization earlier in the treatment paradigm including in patients experiencing their first recurrence.

 

  •  

Maintenance of strong patient access and expansion of payer coverage for VOWST across Commercial and Medicare Part D plans.

 

  •  

Increasing penetration of the hospital outflow patient segment.

 

  •  

SER-155 Phase 1b placebo-controlled Cohort 2 data readout anticipated in third quarter of 2024.

Seres ended 2023 with preliminary cash, cash equivalents and investments of approximately $128 million (unaudited). Seres anticipates that this year-end cash balance, in conjunction with the anticipated savings from the restructuring announced in November 2023 and the expected receipt of the $45 million Tranche B under its existing senior secured debt facility (the Term Loan Facility) with Oaktree Capital Management, L.P. (Oaktree), will support its operations into the fourth quarter of 2024.

INDICATION AND IMPORTANT SAFETY INFORMATION FOR VOWST

INDICATION

VOWST is indicated to prevent the recurrence of Clostridioides difficile infection (CDI) in individuals 18 years of age and older following antibacterial treatment for recurrent CDI.

Limitation of Use: VOWST is not indicated for treatment of CDI.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Transmissible infectious agents: Because VOWST is manufactured from human fecal matter, it may carry a risk of transmitting infectious agents. Report any infection that is suspected to have been transmitted by VOWST to Aimmune Therapeutics, Inc. at 1-833-246-2566.

Potential presence of food allergens: VOWST may contain food allergens. The potential to cause adverse reactions due to food allergens is unknown.

ADVERSE REACTIONS

The most common adverse reactions (reported in ≥5% of participants) were abdominal distension (31.1%), fatigue (22.2%), constipation (14.4%), chills (11.1%), and diarrhea (10.0%).

To report SUSPECTED ADVERSE REACTIONS, contact Aimmune Therapeutics at 1-833-AIM-2KNO (1-833-246-2566), or the FDA at 1-800-FDA-1088, or visit www.fda.gov/MedWatch.

DRUG INTERACTIONS

Do not administer antibacterials concurrently with VOWST.

Please see Full Prescribing Information and Patient Information

About Seres Therapeutics

Seres Therapeutics, Inc. (Nasdaq: MCRB) is a commercial-stage company developing novel microbiome therapeutics for serious diseases. Seres’ lead program, VOWST™, obtained U.S. FDA approval in April 2023 as the first orally administered microbiome therapeutic to prevent recurrence of C. difficile infection (CDI) in adults following antibacterial treatment for recurrent CDI and is being commercialized in collaboration with Nestlé Health Science. Seres is evaluating SER-155 in a Phase 1b study in patients receiving allogeneic hematopoietic stem cell transplantation. For more information, please visit www.serestherapeutics.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including the commercial success and continued growth of VOWST, the timing and results of our clinical studies, access to additional debt tranches, the sufficiency of cash to fund operations, and other statements which are not historical fact.

These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: we have incurred significant losses, are not currently profitable and may never become profitable; our need for additional funding; our limited operating history; our novel approach to therapeutic intervention; our reliance on third parties and collaborators to conduct our clinical trials, manufacture our product or product candidates and develop and commercialize our product or product candidates, if approved; the unknown degree and competing factors of market acceptance for VOWST; the competition we will face; our ability to protect our intellectual property; and our ability to retain key personnel and to manage our growth. These and other important factors discussed under the caption “Risk Factors” in our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC), on November 2, 2023, and our other reports filed with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

Investor and Media:

Rob Windsor

Rwindsor@serestherapeutics.com

###

EX-101.SCH 3 mcrb-20240109.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 mcrb-20240109_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 mcrb-20240109_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g129973g0110045634462.jpg GRAPHIC begin 644 g129973g0110045634462.jpg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htm IDEA: XBRL DOCUMENT v3.23.4
Document and Entity Information
Jan. 09, 2024
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001609809
Document Type 8-K
Document Period End Date Jan. 09, 2024
Entity Registrant Name SERES THERAPEUTICS, INC.
Entity Incorporation State Country Code DE
Entity File Number 001-37465
Entity Tax Identification Number 27-4326290
Entity Address, Address Line One 101 Cambridgepark Drive
Entity Address, City or Town Cambridge
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02140
City Area Code (617)
Local Phone Number 945-9626
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common stock, par value $0.001 per share
Trading Symbol MCRB
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 d129973d8k_htm.xml IDEA: XBRL DOCUMENT 0001609809 2024-01-09 2024-01-09 false 0001609809 8-K 2024-01-09 SERES THERAPEUTICS, INC. DE 001-37465 27-4326290 101 Cambridgepark Drive Cambridge MA 02140 (617) 945-9626 false false false false Common stock, par value $0.001 per share MCRB NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( XX*E@'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " .."I8\H+\V^X K @ $0 &1O8U!R;W!S+V-O&ULS9+! M:L,P#(9?9?B>R'9'#R;-96.G%@8K;.QF;+4UBQ-C:R1]^SE>FS*V!]C1TN]/ MGT"-"4G_$(09L/ M?420G*_!(VFK2<,,K,)"9&UCC3(1-0WQ@K=FP8?/V!68-8 =>NPI@:@%L':> M&,Y3U\ -,,,(HT_?!;0+L53_Q)8.L$MR2FY)C>-8CZN2RSL(>-MM7\JZE>L3 MZ=Y@_I6621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7 MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 ( M XX*E@C058M5@0 )D0 8 >&PO=V]R:W-H965T&UL MC9AK<^(V%(;_BL;M=-J9!%_"-05F""&[=#=9"FQWIIU^$+8 36S)E>20_/L> MV<2F77/,EV#9/J\?'1V]DC(\2/6L]XP9\IK$0H^OJ<,\2JELR90*> M;*5*J(&FVKDZ58Q&>5 2NX'G==V$'GA4U9'%LEX/CG*.J4W[2!I]?O MZ@]YYZ$S&ZK95,;?>&3V(Z?OD(AM:1:;I3Q\9,<.=:Q>*&.=_R6'XMVVYY P MTT8FQV @2+@H?NGK,1&G ?Z9@. 8$.3FR%^3C38*AO#O.J)"H5VO M8.OZ5JE&?P(::[.CH\?DMC MS1".=LG11G6.8S<%$D5C&,.(O9)/[*V."%?R/ ]R,^A[ P2K4V)U4+&ROM9O M*:MCP'[&4(W*.D&E] ]\)B1IRS9,%4'@FM Q5_?]-K= M#L+C>Y6E>I<0K>DKF4=0=GS+PR)IY_D:)(/>=?LFZ 8##R,\,7W_$L))%($A MZJOW"_(9WB-?1.U0-DCZGD^F--DH'NU82M4SN5>PWF*XU1+@HP[^'>[4MJ0B M:WFH7Z%PN1(3@ZO\W\<-_/]PQ<0 NH62+UR$]V;\<+TFLJ"R_P#WZN_(YEIG0-8$V"#;"%BY?X!;]8J%F;+3SP\V9,U-7#O] M&D1L#V%%@P-*^'Q%P/#)"XTS1G[T6K":DA1ZJO=4H<0G9P#*1K;R5F_) M1M;678/ XW1YAY%4;A_@SESF;O8:[JG8L;/;M0:AI\GJ?O([QE39?'"1S<\2 MIG8V2Q] P>QM#:94U!X &@3/EII[F#9JC@'%PTC MT_SLN9$&3K+YY9Y1F ;V!7B^E=*\-^QQMOQOQ/A?4$L#!!0 ( XX*EB? MH!OPL0( .(, - >&PO9KEMW MDOSAR+DCO9*ZW="C<\W[)&D/1ZY8^\XT7'ND,E8QYU5;)VUC.2M;<%(R6=[< M9(EB0M-BK3MUIUQ+#J;3;D-O:%*L*Z//EI0&@U_*%">/3&[HEDFQMV)8RY20 MIV!>@N%@I+'$>2I\0Q=@:9\"O @:L!SC**&-!6,2,H3O_;C\&3!IK5>%E#/! M)0V&8MTPY[C5=UX9%@_&%Q 9Y=VI\0QKRTZ+Y2T].PP_/LG>V)+;.'36-/+T08I:*Q[V_LL)BS6;_,C16/'DL\&D'+R!6TH>N77B<&GY85FS MX[V;IJFO<,[+?Y#SGZUSS36W3%Z2]J/_-U?Y+8R3\?1<'-&K SI;"5R$&_H5 M[E=YYD#VG9!.Z%$[BK+D^L4Y]>$=V_L+_"J^7U_RBG72[69P0\_R%UZ*3N7S MJGNHR[CJ+'^&^VB1S;>PSR5TR7M>;D?5UOM!)%[P6<<'')XC=\,31S"?@,41 MP+ \& /,)WAA>?ZG_:S0_00,X[:*(BO49X7Z!*\8LAT^6)ZX3^Z?^$[S/$VS M#*OH=AMEL,7JEF7P%X^&<0,/+ ]D>ENM\6[C$_+Z'& ]?6U"L)WBDXCM%*\U M(/&Z@4>>Q[N-Y0$/K O8[$#^>!Z8J;A/FD)7,6[8"<:1/,<0F,7XC&894IT, M/O'^8* \^>Q\ETWLJ.?]74_P$4$L# M!!0 ( XX*EB7BKL

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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.4 html 1 22 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://serestherapeutics.com//20240109/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d129973d8k.htm mcrb-20240109.xsd mcrb-20240109_lab.xml mcrb-20240109_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "d129973d8k.htm": { "nsprefix": "mcrb", "nsuri": "http://serestherapeutics.com/20240109", "dts": { "inline": { "local": [ "d129973d8k.htm" ] }, "schema": { "local": [ "mcrb-20240109.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd" ] }, "labelLink": { "local": [ "mcrb-20240109_lab.xml" ] }, "presentationLink": { "local": [ "mcrb-20240109_pre.xml" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 23, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://serestherapeutics.com//20240109/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "duration_2024-01-09_to_2024-01-09", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d129973d8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "duration_2024-01-09_to_2024-01-09", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d129973d8k.htm", "first": true, "unique": true } } }, "tag": { "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://serestherapeutics.com//20240109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://serestherapeutics.com//20240109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://serestherapeutics.com//20240109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://serestherapeutics.com//20240109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://serestherapeutics.com//20240109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://serestherapeutics.com//20240109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://serestherapeutics.com//20240109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://serestherapeutics.com//20240109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://serestherapeutics.com//20240109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://serestherapeutics.com//20240109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://serestherapeutics.com//20240109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://serestherapeutics.com//20240109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://serestherapeutics.com//20240109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://serestherapeutics.com//20240109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security 12b Title", "terseLabel": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://serestherapeutics.com//20240109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://serestherapeutics.com//20240109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://serestherapeutics.com//20240109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://serestherapeutics.com//20240109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://serestherapeutics.com//20240109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://serestherapeutics.com//20240109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://serestherapeutics.com//20240109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://serestherapeutics.com//20240109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 15 0001193125-24-005614-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-24-005614-xbrl.zip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